Landscape

The following websites provide comprehensive updates on the progress of COVID-19 vaccine development:

 

Milken Institute Vaccine Tracker

 

New York Times COVID-19 Vaccine Tracker

 

  

 

 NCIRS Vaccine Landscape

 

WHO Vaccine Landscape

 

Clinical trials of COVID-19 vaccine candidates currently occurring in Australia:

Sponsor: Novavax
Location: Phase I and Phase II - Nucleus Network, Herston, Queensland (Qld) and Melbourne, Victoria (Vic).  Phase II - Paratus Clinical Research, Canberra, Western Sydney and Central Coast, New South Wales (NSW); Australian Clinical Research Network, Maroubra, NSW; Scentia Clinical Research Ltd, Randwick, NSW; University of the Sunshine Coast, Morayfield and Sippy Downs, Qld; Barwon Health, Geelong, Vic.
Clinical Trial Registry ID: NCT04368988
Study phase: I/II
Vaccine platform: Recombinant protein nanoparticle with proprietary Matrix-M adjuvant (SARS-CoV-2 rS)
Study start date: 25 May, 2020
Estimated study completion date: 18 November, 2021
Number of participants: Phase I - 131 (aged 18 years to 59 years, inclusive); Phase II - 1500 (aged 18 to 84 years, inclusive)
Phase I Intervention Arms: placebo, 5µg or 25µg plus adjuvant or 25µg without adjuvant; 2-dose schedule on Days 0 and 21 with one arm receiving single dose only of 25µg plus adjuvant on Day 0 and placebo on Day 21.
Phase II Intervention Arms: placebo on Days 0, 21 and 189; 2 doses of 5µg plus adjuvant on Days 0 and 21, followed by placebo on Day 189; 2 doses of 25µg plus adjuvant on Days 0 and 21, followed by placebo on Day 189; alternating dose of 5µg plus adjuvant on Day 0, placebo on Day 21 and 5µg plus adjuvant on Day 189; alternating dose of 25µg plus adjuvant on Day 0, placebo on Day 21 and 5µg plus adjuvant on Day 189;   

Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
Location: Linear Clinical Research Ltd, Perth, Western Australia
Clinical Trial Registry ID: NCT04405908
Study phase: I
Vaccine platform: Trimeric S-protein
Study start date: 19 June, 2020
Estimated study completion date: 30 March, 2021
Number of participants: 150 (90 adults aged 18 to 54 years inclusive & 60 older adults aged 55 to 75 years of age, inclusive)
Intervention Arms: 
  • Adult cohort: 2-dose schedule of 3µg to 30µg with and without ASO3 adjuvant; 2-dose schedule of 3µg to 30µg with and without CpG1018 plus Alum adjuvant. 
  • Older adult cohort: 2-dose schedule of 3µg to 30µg with ASO3 adjuvant or CpG1018 plus Alum adjuvant.

Sponsor: Vaxine Pty Ltd
Location: PARC Clinical Research, Adelaide, South Australia
Clinical Trial Registry ID: NCT04453852
Study phase: I
Vaccine platform: Recombinant spike protein with Advax-SM adjuvant
Study start date: 30 June, 2020
Estimated study completion date: 1 July, 2021
Number of participants: 40 (aged 18 years to 65 years)
Intervention Arms: 2-dose schedule of spike antigen (25µg) + 15mg Advax-2 adjuvant or saline control.

Sponsor: University of Queensland
Location: Nucleus Network Brisbane (Q Pharm Pty Ltd), Herston, Queensland
Clinical Trial Registry ID: NCT04495933
Study phase: I
Vaccine platform: Adjuvanted Sclamp protein subunit vaccine
Study start date: 13 July 2020
Estimated study completion date: September 2021
Number of participants: 216 (120 adults aged 18 years to 55 years of age, inclusive and 96 older adults aged 56 years of age and older)
Intervention Arms: 2-dose schedule of 5µg, 15µg or 45µg of adjuvanted Sclamp vaccine or placebo.

Sponsor: Serum Institute of India Pvt Ltd
Location: Nucleus Network, Melbourne, Victoria
Clinical Trial Registry ID: ACTRN12620000817943p
Study Phase: I/II
Vaccine platform: Subunit vaccine  - Receptor Binding Domain (RBD) SARS-CoV-2 Hepatitis B surface antigen (HBsAg) virus like particle vaccine
Study start date: 22 August 2020
Estimated study completion date: 30 March 2021
Number of participants: 280 (phase I component adults aged 18 - 45 years of age, inclusive; phase II component adults aged 18 to 79 years, inclusive)
Intervention Arms: Phase I component - 2 dose schedule of 5µg or 25µg of subunit vaccine or placebo; Phase II component - 2 dose schedule of 5µg or 25µg of subunit vaccine or placebo or single dose of 5µg or 25µg on Day 0 and placebo on Day 28

Sponsor: Symvivo Corporation
Location: Nucleus Network, Brisbane, Queensland
Clinical Trial Registry ID: NCT04334980
Study Phase: I
Vaccine platform: bacTRL-Spike (oral dose)
Study start date: 2 November 2020
Estimated study completion date: 28 February 2022
Number of participants: 12 (adults aged 18 years and older; older adults aged 56 years and older)
Intervention Arms: Single dose of bacTRL-Spike, equivalent to 1 billion colony forming units (cfu) of Bifidobacterium longum (B. Longum); Single dose of bacTRL-Spike, equivalent to 3 billion cfu of B. Longum;  Single dose of bacTRL-Spike, equivalent to 10 billion cfu of B. Longum; and DSMB-defined dose of bac-TRL-Spike in participants aged 56 years of age and older.